4//SEC Filing
Jabbour Jerome D 4
Accession 0000905718-21-000830
CIK 0001582554other
Filed
Jun 23, 8:00 PM ET
Accepted
Jun 24, 5:49 PM ET
Size
9.4 KB
Accession
0000905718-21-000830
Insider Transaction Report
Form 4
Jabbour Jerome D
DirectorPresident and CEO
Transactions
- Conversion
Series B Preferred Stock
2021-06-19−15→ 0 totalExercise: $0.50From: 2018-06-21→ Common Stock (30,000 underlying) - Conversion
Common Stock, par value $0.0001 per share
2021-06-19+30,000→ 840,011 total - Other
Common Stock, par value $0.0001 per share
2021-06-19+6,000→ 810,011 total
Footnotes (2)
- [F1]Stock dividend, payable to all holders of record of Series B Preferred Stock of 400 shares of Common Stock for each share of Series B Preferred Stock.
- [F2]On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the "Certificate") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date.
Documents
Issuer
Matinas BioPharma Holdings, Inc.
CIK 0001582554
Entity typeother
Related Parties
1- filerCIK 0001698838
Filing Metadata
- Form type
- 4
- Filed
- Jun 23, 8:00 PM ET
- Accepted
- Jun 24, 5:49 PM ET
- Size
- 9.4 KB